Premium
Serum interleukin‐17 as a novel biomarker in patients with acne vulgaris
Author(s) -
Ebrahim Adel A.,
Mustafa Amany Ibrahim,
ElAbd Awad Mohamed
Publication year - 2019
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12934
Subject(s) - acne , medicine , pathogenesis , biomarker , disease , interleukin , immunology , gastroenterology , dermatology , cytokine , biology , biochemistry
Background Acne vulgaris is a common chronic inflammatory skin disease involving pilosebaceous units. Both innate and adaptive immunity, especially the T helper 17 pathway, may contribute to the inflammatory response in acne. Objectives We aimed at evaluation of serum interleukin‐17 (IL‐17) level in patients with acne vulgaris in order to assess its role in disease pathogenesis and its clinical significance. Methods Serum IL‐17 level was measured by an ELISA technique in 80 acne vulgaris patients and 80 apparently healthy controls. Results Serum IL‐17 level was significantly higher in acne vulgaris patients than control group ( P < 0.001). Moreover, it was increasing significantly with the increase in disease severity and in patients with scarring lesions ( P < 0.001 each). Conclusions Serum IL‐17 is not only a biomarker of disease pathogenesis but also it could be a potential prognostic predictor for severity and scarring in acne vulgaris.